Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Estrogen receptor alpha (ERα) signaling is crucial in breast cancer, with disruptions contributing to disease progression.
• MicroRNAs (miRNAs) are increasingly recognized as regulators of ERα activity in breast carcinomas.
• Alterations in both ERα and miRNA expression correlate with cancer progression.

Purpose of the Study:

• To investigate the role of Argonaute 2 (AGO2) in ERα signaling and its correlation with breast cancer subtypes and clinical outcomes.
• To determine how AGO2 overexpression affects ERα downstream signaling and gene expression in breast cancer cells.

Main Methods:

• Correlation analysis of AGO2 expression with breast cancer subtypes (luminal B) and clinical outcomes in ERα+ tumors.
• In vitro studies using MCF-7 breast cancer cells overexpressing AGO2 (MCF7-AGO2) to assess ERα signaling pathway alterations.
• Quantitative polymerase chain reaction (qPCR) to measure gene expression levels of ERα, ERα-36, and progesterone receptor.

Main Results:

• High AGO2 expression was found to correlate with the luminal B breast cancer subtype and poor clinical outcome in ERα+ tumors.
• MCF7-AGO2 cells exhibited altered ERα downstream signaling, with enhanced ERα-36 expression.
• Decreased basal expression of full-length ERα and progesterone receptor genes, and loss of estrogen-stimulated gene expression were observed in MCF7-AGO2 cells.
• Despite altered gene expression, MCF-7-AGO2 cells showed increased estrogen-stimulated tumorigenesis in vivo.

Conclusions:

• AGO2 is suggested to be a regulator of altered ERα signaling in breast tumors.
• The findings link AGO2 expression to aggressive breast cancer subtypes and poor prognosis.
• AGO2 may represent a potential therapeutic target for managing breast cancer with altered ERα signaling.